MAKO is a 2 year study testing the safety and efficacy of the squalamine eye drop as a potential wet macular degeneration treatment. This study will determine whether the drop provides an added benefit to standard anti-VEGF therapy. Squalamine is an anti-angiogenic drug that works against abnormal neovascularization by inhibiting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (BFGF). This study is sponsored by Ohr Pharmaceutical Inc.
For more information or to see if you qualify for the study, contact our research department at email@example.com or (212) 452-6965. You may also visit the MAKO Clinical Trials website.
Let us help you enjoy your lifeCall: (212) 861-9797
To Speak With An Appointment Coordinator Now